Tag
The FDA granted full clinical approval to Leqembi (lecanemab) on Thursday, July 6, making it only the second new drug…
Medicare coverage of new Alzheimer’s treatments will raise premiums and increase out-of-pocket costs for beneficiaries, new analysis finds.
Cases of Alzheimer’s disease are rising throughout the world and could triple by 2050, according to a recent analysis in The…
This is part 2 of a package on sponsored disease awareness campaigns and other controversial drug marketing practices, focusing on…
New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even…
Editor’s Note: This is part 2 of a two-part package on the pipeline for Alzheimer’s disease drugs. Check out part…
Eli Lilly recently announced that the FDA had granted a breakthrough therapy designation for donanemab, its investigational antibody therapy for…
Liz Seegert, AHCJ’s topic leader on aging, contributed to this article. Federal policy experts and the influential Institute for Clinical…
Part two of two parts; the first ran Thursday, June 10. There’s still a great deal we don’t yet understand…
Part one of two parts; the second runs tomorrow, Friday, June 11. You might think that the first new drug…